At least one late-stage clinical trial will likely provide data to support the safety and efficacy of an emerging coronavirus disease 2019 (COVID-19) vaccine candidate by the end of this year, but there are concerns that the lack of long-term safety data and the rush to approve a vaccine before November could pose potential health risks to the public.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,